CELLULAR KINETICS OF ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, LISOCABTAGENE MARALEUCEL (LISO-CEL) AND ITS ASSOCIATION WITH EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

被引：0
|
作者：
Nishii, R. [1 ]
Lin, H. [1 ]
Chen, W. [1 ]
Balasubramanian, N. [1 ]
Cummings, J. [1 ]
Farazi, T. [1 ]
Fasan, O. [1 ]
Vedal, M. [1 ]
Lymp, J. [1 ]
Ogasawara, K. [1 ]
机构：
[1] Bristol Myers Squibb, Summit, NJ USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-016
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [31] KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL): Results from Phase 2 of ZUMA-2
    Wang, Michael
    Munoz, Javier
    Goy, Andre
    Locke, Frederick L.
    Jacobson, Caron A.
    Hill, Brian T.
    Timmerman, John M.
    Holmes, Houston
    Jaglowski, Samantha
    Flinn, Ian W.
    McSweeney, Peter A.
    Miklos, David B.
    Pagel, John M.
    Kersten, Marie Jose
    Peng, Weimin
    Zheng, Lianqing
    Rossi, John M.
    Jain, Rajul K.
    Rao, Arati V.
    Reagan, Patrick M.
    MOLECULAR THERAPY, 2020, 28 (04) : 573 - 573
  • [32] Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy
    Siddiqi, Tanya
    Jaeger, Ulrich
    Moshkovich, Olga
    Devlen, Jennifer
    Miera, Matthew
    Williams, Agnes
    Hasskarl, Jens
    Liu, Fei Fei
    Braverman, Julia
    Salles, Gilles
    BLOOD, 2020, 136
  • [33] Developing a Novel Anti-CD19/CD20 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cell Therapy for Relapsed/Refractory (r/r) B-Cell NHL
    Zhou, Lili
    Huang, Jiaqi
    Zhu, Shigui
    Yao, Xin
    Ye, Shiguang
    Zhu, Judy
    Zheng, Chengxiao
    Chen, Shiyi
    Li, Yanfeng
    Lan, Liping
    Chen, Shicheng
    Guo, Lin
    Zhang, Qingsong
    Zheng, Jiangqin
    Wang, Rirfei
    Hong, Yi
    Ren, Jiaqiang
    Zhang, Li
    Zhang, Wenjun
    Tang, Xiaochen
    Wang, Junbang
    Liu, Jie
    Humphries, Michael
    Li, Ping
    Yao, Yihong
    Liang, Aibin
    BLOOD, 2020, 136
  • [34] EFFICACY AND TOXICITY FOR CD7 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/ REFRACTORY T-CELL LYMPHOMA
    Su, Guoai
    Yang, Fan
    Shi, Hui
    Liu, Rui
    Li, Ruiting
    Xu, Teng
    Feng, Shaoma
    Zheng, Peihao
    Guo, Yuelu
    Ma, Lixia
    Deng, Biping
    Ke, Xiaoyan
    Hu, Kai
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 196 - 197
  • [35] Lisocabtagene maraleucel (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.
    Abramson, Jeremy S.
    Palomba, Maria Lia
    Arnason, Jon E.
    Lunning, Matthew Alexander
    Solomon, Scott R.
    Farazi, Thalia
    Garcia, Jacob
    Xie, Benhuai
    Newhall, Kathryn J.
    Dehner, Christine
    Siddiqi, Tanya
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Prophylactic Tocilizumab in Patients with Relapsed Refractory Lymphoma Treated with Anti CD19 Chimeric Antigen Receptor T-Cell Therapy
    Ahmed, Nausheen
    Caimi, Paolo
    Reese, Jane S.
    Otegbeye, Folashade
    Patel, Seema
    Schneider, Dina
    Boughan, Kirsten M.
    Cooper, Brenda
    Gallogly, Molly
    Kruger, Winfred
    Worden, Andrew
    Kadan, Michael
    Lopes, Filipa Blasco Tavares Pereira
    Sharma, Ashish
    Malek, Ehsan
    Metheny, Leland
    Tomlinson, Benjamin
    Wald, David
    Sekaly, Rafick-Pierre
    Orentas, Rimas
    Dropulic, Boro
    de Lima, Marcos
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S275 - S276
  • [37] Primary Results From OUTREACH: A Phase II Study of Lisocabtagene Maraleucel (Liso-Cel) Administered in the Community Setting as Outpatient or Inpatient Treatment in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Linhares, Yuliya
    Freytes, Cesar
    Cherry, Mohamad
    Bachier, Carlos
    Maris, Michael
    Hoda, Daanish
    Varela, Juan C.
    Bellomo, Courtney
    Cross, Scott
    Essell, James
    Fanning, Suzanne
    Terebelo, Howard
    Yimer, Habte
    Courtright, Jay
    Sharman, Jeff P.
    Kostic, Ana
    Vedal, Min
    Ogasawara, Ken
    Avilion, Ariel
    Espinola, Ricardo
    Yuan, Brenda
    Mattar, Bassam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S514 - S515
  • [38] Matching-Adjusted Indirect Comparison (MAIC) of Axicabtagene Ciloleucel (Axi-Cel) and Lisocabtagene Maraleucel (Liso-Cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After Two or More Prior Lines of Therapy
    Oluwole, Olalekan O.
    Chen, Jenny M. H.
    Chan, Keith
    Patel, Anik R.
    Jansen, Jeroen P.
    Keeping, Sam
    Bashir, Zahid
    Zheng, Yan
    Snider, Julia
    Locke, Frederick L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S388 - S388
  • [39] Efficacy and Safety Study of Chimeric Antigen Receptor-T Cell Therapy for People with Relapsed/Refractory Follicular Lymphoma
    Xu, Ting
    Zeng, Liangyu
    Wu, Depei
    Li, Caixia
    BLOOD, 2024, 144 : 7801 - 7801
  • [40] Phase 3 TRANSFORM study of lisocabtagen maraleucel (Liso-Cel), a CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, versus standard of care (SOC) as second-line therapy (2L) in patients (pt) with relapsed or refractory large B-cell lymphoma (LBCL)
    Glass, B.
    Kamdar, M.
    Solomon, S. R.
    Arnason, J.
    Johnston, P. B.
    Ibrahimi, S.
    Mielke, S.
    Mutsaers, P.
    Hernandez-Ilizaliturri, F.
    Izutsu, K.
    Morschhauser, F.
    Lunning, M.
    Maloney, D. G.
    Crotta, A.
    Montheard, S.
    Previtali, A.
    Stepan, L.
    Ogasawara, K.
    Abramson, J. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 194 - 194
12345